Simplify Logo

Full-Time

Research Automation Lead

Confirmed live in the last 24 hours

Retro Biosciences

Retro Biosciences

51-200 employees

Develops therapeutics targeting aging mechanisms

Biotechnology
Healthcare

Compensation Overview

$150k - $190kAnnually

Senior, Expert

San Carlos, CA, USA

Category
Bioinformatics
Genomics
Biology Lab & Research
Biology & Biotech
Required Skills
Python
Requirements
  • Highly knowledgeable in a bio/technical or bioengineering discipline with 5+ years of relevant experience.
  • Have led the deployment of automated cell culture systems.
  • Experience working in a fast-paced startup environment.
  • Knowledge of commercial liquid handling systems.
  • Experience with assay development.
  • Proficiency with any major programming language (especially python).
  • Experience with one or more of the following standard life-science application areas: microbiology, molecular biology, flow cytometry, high content analysis (HCA), high throughput screening (HTS), genomics, and sequencing.
Responsibilities
  • Work cross-functionally to develop a deep understanding of the scientific processes and identify the key bottlenecks that could be improved with automation.
  • Research and continually develop your knowledge of state-of-the-art tools that Retro can use to advance our research in innovative ways.
  • Work in lock-step with scientific teams to automate key experiments and increase research velocity, as well as develop novel assays in-house.
  • Develop a deep understanding of the skills within the automation team in order to most effectively allocate team time and resources.
  • Work as a collaborative leader to align automation team on the highest-impact work for Retro as a whole.

Retro Biosciences focuses on extending healthy human lifespan by developing therapeutics that target the cellular mechanisms of aging. The company works on three main programs: cellular reprogramming, plasma-inspired therapeutics, and autophagy, each at different stages of development. By addressing the root causes of age-related diseases, Retro Biosciences aims to reduce healthcare costs associated with these conditions, which make up a significant portion of U.S. healthcare spending. The company utilizes advanced technologies like single-cell multi-omics and computational biology to support its research. With $180 million in funding, Retro Biosciences is positioned to advance its therapeutic candidates towards clinical applications, aiming to make significant contributions to age-related disease prevention.

Company Stage

Pre-seed

Total Funding

$180M

Headquarters

San Francisco, California

Founded

2021

Growth & Insights
Headcount

6 month growth

11%

1 year growth

28%

2 year growth

205%
Simplify Jobs

Simplify's Take

What believers are saying

  • Retro Biosciences' mission to extend healthy human lifespan by ten years offers a compelling and impactful vision for employees.
  • The company's robust pipeline and advanced technologies like single-cell multi-omics and computational biology provide ample opportunities for innovation and career growth.
  • Strong financial backing and high-profile investments, such as from Sam Altman, ensure long-term stability and resources for research and development.

What critics are saying

  • The ambitious goal of extending human lifespan by ten years involves high scientific and regulatory uncertainties.
  • Dependence on successful clinical trials and commercialization of therapeutic candidates poses significant risks.

What makes Retro Biosciences unique

  • Retro Biosciences focuses on extending healthy human lifespan by targeting the cellular mechanisms of aging, a unique approach compared to traditional biotech firms.
  • Their diversified business model, which includes cellular reprogramming, plasma-inspired therapeutics, and autophagy, provides a balanced pipeline of potential treatments.
  • Significant initial funding of $180 million and partnerships like the $85 million deal with Multiply Labs for automated cell therapy manufacturing set Retro Biosciences apart in terms of financial backing and technological advancement.